1
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Marc J Ostro, Micrea C Popescu: Stable plurilamellar vesicles, their preparation and use. The Liposome Company, Pennie & Edmonds, June 11, 1985: US04522803 (204 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.


2
Mircea Popescu, Christine E Swenson, Sterling C Johnson, Robert P Lenk: Therapeutic treatment by intramammary infusion. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, January 1, 1991: US04981692 (78 worldwide citation)

A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or ...


3
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Ronald G Ort, December 8, 1992: US05169637 (71 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


4
Robert P Lenk, Anthony G Durning, Robert J Klimchak, Joel Portnoff, Michelle L Tomsho: Method for size separation of particles. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, September 7, 1999: US05948441 (69 worldwide citation)

Tangential flow filtration is used in the size separation of particles, such as liposomes and lipid particles. These particles may be passed through a tangential flow filtration device of any pore size desired. Tangential flow filter systems of various pore sizes may be used sequentially to obtain p ...


5
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, July 9, 1991: US05030453 (68 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


6
Andrew S Janoff, Mircea C Popescu, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Catherine L Kurtz, October 22, 1991: US05059591 (49 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


7
Michael W Fountain, Steven J Weiss, Robert P Lenk, Mircea C Popescu, Richard S Ginsberg: Enhancement of pharmaceutical activity. The Liposome Company, Allen Bloom, Thomas S Saunders, Ronald G Ort, March 19, 1991: US05000958 (38 worldwide citation)

The invention encompasses mixtures of antimicrobial agents coencapsulated in liposomes which when administered in vivo exert an enhanced therapeutic effect. The therapeutic effectiveness of the coencapsulated antimocrobial agents is greater than that of the same combination administered either in so ...


8
Andrew S Janoff, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Mircea C Popescu, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Thomas M Saunders, January 30, 1990: US04897384 (34 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


9
Kapil Mehta, Roman Perez Soler, Gabriel Lopez Berestein, Robert P Lenk, Alan C Hayman deceased: Formulation and use of carotenoids in treatment of cancer. Board of Regents the University of Texas, Aronex Pharmaceuticals, Arnold White & Durkee, September 22, 1998: US05811119 (33 worldwide citation)

A reduced-toxicity formulation of carotenoids is disclosed which is stable in an aqueous environment. The formulation includes a carotenoid, lipid carrier particles (such as liposomes), and an intercalation promoter agent (such as a triglyceride), which causes the carotenoid to be substantially unif ...


10
Andrew S Janoff, Lawrence Boni, Thomas D Madden, Pieter R Cullis, Robert P Lenk, John J Kearns, Anthony G Durning, Robert Klimchak, Joel Portnoff: Low toxicity drug-lipid systems. The Liposome Company, Kenneth B Rubin, April 1, 1997: US05616334 (27 worldwide citation)

Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylgly ...